Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats

References

• Krishnaiah YS. Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs. J Bioequiv Availab. 2010;2(02):28–36. doi:10.4172/jbb.1000027
   Google Scholar
• Lerisko-iversidge EM, Liversidge GG. Drug Nanoparticles: formulating Poorly Water-Soluble Compounds. Toxicol Pathol. 2008;36:43–48. doi:10.1177/019262330731094618337220
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769. doi:10.1038/sj.clpt.610040017957183
   PubMed Web of Science ®Google Scholar
• Hirn S, Semmler-Behnke M, Schleh C, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011;77(3):407–416. doi:10.1016/j.ejpb.2010.12.02921195759
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MA, Delgado A, Évora C, Del Pozo-Rodríguez A, Rodríguez-Gascón A. Biodistribution of Nanostructured Lipid Carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 2013;84(2):309–314. doi:10.1016/j.ejpb.2013.01.02923461861
   PubMed Web of Science ®Google Scholar
• Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–627. doi:10.1038/nrd259120616808
   PubMed Web of Science ®Google Scholar
• Sanvicens N, Marco MP. Multifunctional nanoparticles - properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26:425–433. doi:10.1016/j.tibtech.2008.04.00518514941
   PubMed Web of Science ®Google Scholar
• Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161–172. doi:10.1016/j.ejpb.2008.09.00318824097
   PubMed Web of Science ®Google Scholar
• Esposito E, Boschi A, Ravani L, et al. Biodistribution of nanostructured lipid carriers: A tomographic study. Eur J Pharm Biopharm. 2015;89:145–156. doi:10.1016/j.ejpb.2014.12.00625497177
   PubMed Web of Science ®Google Scholar
• Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93–102. doi:10.1016/j.ijpharm.2005.10.01016303268
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Rh M. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–1272. doi:10.1016/j.addr.2003.12.00215109768
   PubMed Web of Science ®Google Scholar
• Jamal JA, Ghafar ZA, Husain K. Medicinal plants used for postnatal care in Malay traditional medicine in the Peninsular Malaysia. Pharmacogn J. 2011;3(24):15–24. doi:10.5530/pj.2011.24.4
   Google Scholar
• Balaha MF, Tanaka H, Yamashita H, Abdel Rahman MN, Inagaki N. Oral Nigella sativa oil ameliorates ovalbumin-induced bronchial asthma in mice. Int Immunopharmacol. 2012;14(2):224–231. doi:10.1016/j.intimp.2012.06.02322800928
   PubMed Web of Science ®Google Scholar
• Gali-Muhtasib H, Roessner A, Thymoquinone: S-SR. A promising anti-cancer drug from natural sources. Int J Biochem Cell Biol. 2006;38(8):1249–1253. doi:10.1016/j.biocel.2005.10.00916314136
   PubMed Web of Science ®Google Scholar
• Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phyther Res. 2003;17(4):299–305. doi:10.1002/ptr.1309
   PubMed Web of Science ®Google Scholar
• Ahmad A, Husain A, Mujeeb M, et al. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–352. doi:10.1016/S2221-1691(13)60075-123646296
   PubMedGoogle Scholar
• Keh ET, Ashour MMS, Al-Harbi MM. The respiratory effects of the volatile oil of the black seed (Nigella sativa) in guinea-pigs: elucidation of the mechanism(s) of action. Gen Pharmacol. 1993;24(5):1115–1122. doi:10.1016/0306-3623(93)90358-58270170
   PubMedGoogle Scholar
• Radad K, Moldzio R, Taha M, Rausch WD. Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phyther Res. 2009;23(5):696–700. doi:10.1002/ptr.2708
   PubMed Web of Science ®Google Scholar
• Pathan SA, Jain GK, Zaidi SMA, et al. Stability-indicating ultra-performance liquid chromatography method for the estimation of thymoquinone and its application in biopharmaceutical studies. Biomed Chromatogr. 2011;25(5):613–620. doi:10.1002/bmc.149220734352
   PubMed Web of Science ®Google Scholar
• Khader M, Bresgen N, Eckl PM. In vitro toxicological properties of thymoquinone. Food Chem Toxicol. 2009;47(1):129–133. doi:10.1016/j.fct.2008.10.01919010375
   PubMed Web of Science ®Google Scholar
• Ng WK, Saiful Yazan L, Yap LH, et al. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). Biomed Res Int. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Ong YS, Saiful Yazan L, Ng WK, et al. Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice. Int J Nanomedicine. 2016;11:5905‐5915. doi:10.2147/IJN.S114205
   PubMed Web of Science ®Google Scholar
• Shidhaye S, Vaidya R, Sutar S, Patwardhan A, Kadam V. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers – innovative Generations of Solid Lipid Carriers. Curr Drug Deliv. 2008;5(4):324–331. doi:10.2174/15672010878591508718855604
   PubMedGoogle Scholar
• Patidar A, Thakur DS, Kumar P, Verma J. A review on novel lipid based nanocarriers. Int J Pharm Pharm Sci. 2010;2(4):30–35.
   Google Scholar
• Abdelwahab SI, Sheikh BY, Taha MME. et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomedicine;2013 2163–2172. doi:10.2147/IJN.S4410823818776
   PubMed Web of Science ®Google Scholar
• Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Investig. 2013;43(5):353–362. doi:10.1007/s40005-013-0087-y
   Google Scholar
• Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346(1–2):124–132. doi:10.1016/j.ijpharm.2007.05.06017651933
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.1020402623
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497–508. doi:10.1517/17425247.2012.67327822439808
   PubMed Web of Science ®Google Scholar
• Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine. 2011;6:815–835. doi:10.2217/nnm.11.7921793674
   PubMed Web of Science ®Google Scholar
• Hirsjärvi S, Sancey L, Dufort S, et al. Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting. Int J Pharm. 2013;453(2):594–600. doi:10.1016/j.ijpharm.2013.05.05723747436
   PubMedGoogle Scholar
• Ballot S, Noiret N, Hindré F, et al. 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution. Eur J Nucl Med Mol Imaging. 2006;33(5):602–607. doi:10.1007/s00259-005-0007-016450136
   PubMed Web of Science ®Google Scholar
• Di Domenico G, Zavattini G International Atomic Energy Agency, Vienna (Ed.) Advances in SPECT Instrumentation (Including Small Animal Scanners). Technetium-99m Radiopharmaceuticals: Status and Trends: IAEA Radioisotopes and Radiopharmaceuticals Series No., Austria1;200957–90.
   Google Scholar
• Saha GB. Fundamentals of Nuclear Pharmacy. Springer, New York: The Atom; 2010:1–10.
   Google Scholar
• De Barros ALB, De Andrade SF, De Souza Filho JD, Cardoso VN, Alves RJ. Radiolabeling of low molecular weight d-galactose-based glycodendrimer with technetium-99m and biodistribution studies. J Radioanal Nucl Chem. 2013;298:605–609. doi:10.1007/s10967-013-2502-2
   Web of Science ®Google Scholar
• Monteiro LOF, Fernandes RS, Castro LC, et al. Technetium-99 m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo. Biomed Pharmacother. 2017;89:146–151. doi:10.1016/j.biopha.2017.02.00328222395
   PubMed Web of Science ®Google Scholar
• Yang DJ, Kim CG, Schechter NR, et al. Imaging with 99m Tc ECDG Targeted at the Multifunctional Glucose Transport System: feasibility Study with Rodents. Radiology. 2003;226(2):465–473. doi:10.1148/radiol.226201181112563141
   PubMed Web of Science ®Google Scholar
• Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(S1):11–30. doi:10.1007/s00259-011-2001-z
   Google Scholar
• de Barros ALB, Cardoso VN, Mota L, et al. Synthesis and biodistribution studies of carbohydrate derivatives radiolabeled with technetium-99m. Bioorganic Med Chem Lett. 2010;20(1):315–317. doi:10.1016/j.bmcl.2009.10.104
   PubMed Web of Science ®Google Scholar
• Kong FL, Zhang YH, Young DP, Yu DF, Yang DJ. Development of 99mTc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan. Acad Radiol. 2013;20(1):41–51. doi:10.1016/j.acra.2012.08.00522963724
   PubMed Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm - Drug Res. 2010;67(3):217–223.
   PubMed Web of Science ®Google Scholar
• Tiǧli Aydin RS, Pulat M. 5-fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: evaluation of controlled release kinetics. J Nanomater. 2012;2012:1–10. doi:10.1155/2012/313961
   Web of Science ®Google Scholar
• Theobald AE. Quality Control of Radiopharmaceuticals. Textbook of Radiopharmacy: theory and Practice In: Sampson CB, editor. New York: Gordon and Breach; 1990:115–148.
   Google Scholar
• Shah M, Pathak K. Solid Lipid Nanoparticles of Simvastatin: pharmacokinetic and Biodistribution Studies on Swiss albino mice. Res J Pharm Dos Forms Technol. 2012;6:336–342.
   Google Scholar
• Mishra P, Babbar A, Chauhan U. A rapid instant thin layer chromatographic procedure for determining radiochemical purity of99Tcm-IDA agents. Nucl Med Commun. 1991;12(5):467–469. doi:10.1097/00006231-199105000-000132067753
   PubMed Web of Science ®Google Scholar
• Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA. Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats. J Ayub Med Coll Abbottabad. 2008;20(2):25–27.19385451
   PubMedGoogle Scholar
• Yazan LS, Mohd Azlan SN, Zakarial Ansar FH, Gopalsamy B. Acute toxicity study of intravenous administration of thymoquinone-loaded nanostructured lipid carrier (TQ-NLC) in Sprague Dawley rats. Malaysian J Med Heal Sci. 2019;15(2):51–57.
   Google Scholar
• Commission Recommendation of 18 October 2011 on the definition of nanomaterial Text with EEA relevance Official Journal of the European Union 275. 2011:38–40.
   Google Scholar
• Kumar A, Dixit CK. Methods for characterization of nanoparticles In: Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids. 2017:44–58.
   Google Scholar
• Paini M, Daly SR, Aliakbarian B, et al. An efficient liposome based method for antioxidants encapsulation. Colloids Surf B Biointerfaces. 2015;136:1067–1072. doi:10.1016/j.colsurfb.2015.10.03826590900
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Sa W. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(1):131–155. doi:10.1016/S0169-409X(02)00118-7
   PubMed Web of Science ®Google Scholar
• Ong YS, Yazan LS, Ng WK, et al. Thymoquinone loaded in nanostructured lipid carrier showed enhanced anticancer activity in 4T1 tumor-bearing mice. Nanomedicine. 2018;13(13):1567–1582. doi:10.2217/nnm-2017-032230028248
   PubMed Web of Science ®Google Scholar
• Montaner J, Cano-Sarabia M, Simats A, et al. Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. Int J Nanomedicine. 2016;11:3035–3048. doi:10.2147/IJN.S10729227418824
   PubMed Web of Science ®Google Scholar
• How CW, Rasedee A, Manickam S, Rosli R. Rosli R: tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Coll Surf B. 2013;112:393–399. doi:10.1016/j.colsurfb.2013.08.009
   PubMed Web of Science ®Google Scholar
• Araújo J, Garcia ML, Mallandrich M, Souto EB, Calpena AC. Calpena AC: release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomed Nanotechn Biol Med. 2012;8(6):1034–1041. doi:10.1016/j.nano.2011.10.015
   PubMed Web of Science ®Google Scholar
• Siegel RA. Rathbone MJ: overview of Controlled Release Mechanisms In: Fundamentals and Applications of Controlled Release. 2012:19–44.
   Google Scholar
• Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813–830. doi:10.3109/1061186X.2012.71684522931500
   PubMed Web of Science ®Google Scholar
• Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16(5):751–757. doi:10.1023/A:101888892785210350020
   PubMed Web of Science ®Google Scholar
• Neelam S, Hayes PR, Zhang Q, Dickinson RB, Lele TP. Vertical uniformity of cells and nuclei in epithelial monolayers. Sci Rep. 2016;6(1):19689. doi:10.1038/srep1968926795751
   PubMedGoogle Scholar
• Yao M, McClements DJ, Xiao H. Improving oral bioavailability of nutraceuticals by engineered nanoparticle-based delivery systems. Curr Opin Food Sci. 2015;2:14–19. doi:10.1016/j.cofs.2014.12.005
   Web of Science ®Google Scholar
• Chen LC, Wu YH, Liu IH, et al. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol. 2012;39:35–43. doi:10.1016/j.nucmedbio.2011.06.01021958858
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504. doi:10.1021/mp800049w18611037
   PubMed Web of Science ®Google Scholar
• Cole AJ, David AE, Wang J, Galbán CJ, Yang VC. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials. 2011;32(26):6291–6301. doi:10.1016/j.biomaterials.2011.05.02421684593
   PubMed Web of Science ®Google Scholar
• Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. Etoposide loaded PLGA and PCL nanoparticles II: biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv. 2008;15(5):277–287. doi:10.1080/1071754080200650018763158
   PubMed Web of Science ®Google Scholar
• Yan C, Gu J, Guo Y, Chen D. In Vivo Biodistribution for Tumor Targeting of 5-Fluorouracil (5-FU) Loaded N-succinyl-chitosan (Suc-Chi) Nanoparticles. Yakugaku Zasshi. 2010;130(6):801–804. doi:10.1248/yakushi.130.80120519858
   PubMed Web of Science ®Google Scholar
• Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Multiple peaking phenomena in pharmacokinetics disposition. Clini Pharmacokinet. 2010;49(6):351–377. doi:10.2165/11319320-000000000-00000
   PubMed Web of Science ®Google Scholar
• Özcan I, Segura-Sánchez F, Bouchemal K, et al. Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats. Int J Nanomedicine. 2010;5:1103–1111. doi:10.2147/IJN.S1549321270961
   PubMed Web of Science ®Google Scholar
• Kang H, Mintri S, Menon AV, Lee HY, Choi HS, Kim J. Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale. 2015;7(45):18848–18862. doi:10.1039/C5NR05264E26528835
   PubMed Web of Science ®Google Scholar